A record price of $US20 000 has been revealed by manufacturing partners Roche and Trimeris for a one-year supply of their new drug enfuvirtide [`Fuzeon']

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1380, 2003-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A record price of $US20 000 has been revealed by manufacturing partners Roche and Trimeris for a one-year supply of their new drug enfuvirtide [`Fuzeon']

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 405, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

A 23% market share of new prescriptions for hepatitis C in the US has been captured by Roche's antiviral agent PEG-interferon (IFN)- -2a

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 402, 2003-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

New legislation aimed at severing the close ties between the US FDA and drug companies has been introduced in the US.

By  

Inpharma, Vol. 1, Iss. 1488, 2005-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Astellas Pharma's Supplemental New Drug Application (sNDA) for injectable micafungin [Mycamine] has been approved by the US FDA.

By  

Inpharma, Vol. 1, Iss. 1623, 2008-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Reclassification of orlistat [Xenical; Roche] as a pharmacist-only medicine has been recommended in New Zealand (NZ)

By  

Inpharma, Vol. 1, Iss. 1474, 2005-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite